Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka.

In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

This antihypertensive-related article is a stub.

You can help Wikipedia by expanding it.